Real stories. Real impact. A better world.
GOOD NEWS DAILY
AllAnimalsCommunityEconomyEnvironmentHealthHumanityInnovationScienceWeekly Recap

Sugar-Tagged Stem Cells Sent to Bone Marrow Show Early Promise Against Osteoporosis

In a first-in-human trial in Murcia, Spain, 10 women with advanced osteoporosis received their own stem cells with a sugar tag that steers them to bone marrow. No serious side effects occurred and fractures fell sharply, but the study had no control group.

An X-ray image showing the bones of two knee joints
An X-ray image showing the bones of two knee joints. Photo: Taokinesis (Pixabay)

Ten women with advanced osteoporosis who received a single infusion of their own stem cells, chemically tagged to find their way to bone marrow, had no serious side effects and far fewer fractures afterward, according to a first-in-human trial published in Cell on 11 September. In the two years before treatment the group had 16 fragility fractures; in the two years after, they had one.

The phase 1 trial was run at Virgen de la Arrixaca University Hospital in Murcia, Spain, by a team led by hematologist José M. Moraleda of the University of Murcia. The homing technique comes from Robert Sackstein, now at the Miami VA Medical Center, who is the paper's senior author.

Stem cells injected into the blood rarely reach the skeleton

Mesenchymal stem cells, found in bone marrow, can form new bone. Given by intravenous drip, though, they are poor at finding their way to bone, which has limited their use against skeletal disease. The fix is a sugar. In a one-hour enzyme reaction, the team adds fucose to a protein called CD44 on the cell surface, creating a temporary tag that binds a receptor, E-selectin, on blood vessels in the marrow, Chemical & Engineering News reported.

Sackstein first showed the idea in mice. In a 2008 study in Nature Medicine, human stem cells modified this way reached the animals' bone marrow within an hour and formed patches of bone within weeks, Harvard Medical School said at the time. He was then at Brigham and Women's Hospital.

Fracture rate fell from 8 a year to 0.5

The women in the trial were aged 51 to 72, ScienceAlert reported. Doctors took bone marrow from each woman's hip, grew and modified the stem cells in the lab, and infused them back into her bloodstream once. The protocol called for two years of tests, including X-rays, bone scans and blood markers of bone formation, and the team then kept tracking fractures and safety for more than three further years per patient.

Across the group, fractures dropped from 8 a year to 0.5 a year, a 94% reduction. Biopsies taken about four months after infusion showed a significant increase in bone tissue in seven of the 10 women, and volumetric bone mineral density in the forearm was 23% higher at 24 months, according to C&EN.

“The results show that this treatment approach has an excellent safety profile and is feasible.” — José M. Moraleda and colleagues, writing in Cell

The authors also argue that the results contradict the idea that stem cells taken from older people, or from diseased tissue, are too weakened to be useful.

No control group, and outside experts urge caution

The trial was designed to test safety, not effectiveness. It had 10 participants and no randomized comparison group, so it cannot show how many fractures the women would have had without the cells. Outside bone specialists told C&EN it is too early to claim the treatment works.

The researchers say larger trials with more varied patients at more sites are needed before the approach could reach clinics. The trial is registered on ClinicalTrials.gov as NCT02566655. Some cell therapies have already reached routine care: in Berlin, a 19-year-old no longer needs blood transfusions after Germany's first routine CRISPR treatment.

Not medical advice. This article reports on research and health programs for general information. Results from early studies often change in larger trials. Talk to a doctor before making decisions about your own health or treatment.

Sources

How we choose and verify sources: editorial policy.

More stories: Good news from clinical trials (16) →

Explainer: What are the phases of a clinical trial? →

Your weekly dose of good news

The 5 biggest positive stories of the week, straight to your inbox. Free, no noise.